Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Aug 27, 2020
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a new medication called remimazolam on patients undergoing surgery for bladder cancer. Specifically, researchers want to see if using remimazolam for anesthesia can help reduce the chances of experiencing delirium (a sudden change in mental status) after surgery and improve the time patients remain free from cancer recurrence. Delirium can lead to worse outcomes, so understanding the role of remimazolam in this setting is important.
To participate in the study, you should be between 50 and 90 years old and have a diagnosis of non-muscle-invasive bladder cancer. You also need to be scheduled for a specific type of surgery called transurethral resection of bladder tumor (TURBT). If you decide to join, you’ll be asked to sign a consent form, and you can expect to be closely monitored during and after your surgery. This trial is currently recruiting participants, and it aims to help improve care and outcomes for patients with bladder cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥50 years and \<90 years;
- • 2. Preoperative diagnosis is non-muscle-invasive bladder cancer(Ta-T1);
- • 3. Scheduled to undergo transurethral resection of bladder tumor;
- • 4. Agree to participate, and provide written informed consent.
- Exclusion Criteria:
- • 1. Refuse to participate;
- • 2. Emergent surgery;
- • 3. Combined with other malignant tumors;
- • 4. Use of benzodiazepines for 1 week within the last month before surgery;
- • 5. Preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis;
- • 6. Inability to communicate in the preoperative period due to coma, profound dementia, language barrier, or end-stage disease;
- • 7. Critical illness (preoperative American Society of Anesthesiologists physical status classification ≥IV), severe hepatic dysfunction (Child-Pugh class C), or severe renal dysfunction (undergoing dialysis before surgery);
- • 8. The purpose of surgery is to make a diagnosis or preoperative judgement is that tumor cannot be completely removed.
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guiyang, Guizhou, China
Nanjing, Jiangsu, China
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Beijing, Beijing, China
Beijing, Beijing, China
Beijin, Bejing, China
Patients applied
Trial Officials
Wang Dong-Xin, MD, PhD
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials